Thu, January 6, 2022

Matthew Harrison Maintained (BLUE) at Sell with Decreased Target to $10 on, Jan 6th, 2022

Matthew Harrison of Morgan Stanley, Maintained "bluebird bio, Inc." (BLUE) at Sell with Decreased Target from $11 to $10 on, Jan 6th, 2022.

Matthew has made no other calls on BLUE in the last 4 months.



There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Maintained at Hold with Decreased Target to $13 on, Monday, November 8th, 2021


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $10 on, Monday, November 8th, 2021
  • Difei Yang of "Mizuho" Maintained at Strong Buy with Decreased Target to $23 on, Wednesday, September 22nd, 2021